Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations

This publication has 15 references indexed in Scilit:

• Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies
  Medical and Pediatric Oncology, 1997
• Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X
  British Journal of Haematology, 1997
• Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia
  Leukemia Research, 1994
• The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia
  Leukemia Research, 1994
• Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
  Archives of Disease in Childhood, 1993
• Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
  British Journal of Cancer, 1993
• Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
  The Journal of Pediatrics, 1991
• Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
  The Lancet, 1990
• Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council.
  Archives of Disease in Childhood, 1989
• Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.
  British Journal of Clinical Pharmacology, 1983